Menu Close

Sculati Wealth Management LLC Has $2.66 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Sculati Wealth Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 2.8% during the 1st quarter, Holdings Channel reports. The fund owned 15,026 shares of the company’s stock after acquiring an additional 405 shares during the quarter. Johnson & Johnson makes up approximately 1.3% of Sculati Wealth Management LLC’s portfolio, making the stock its 20th biggest position. Sculati Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,663,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the stock. Patron Partners LLC raised its position in shares of Johnson & Johnson by 12.7% during the 1st quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock valued at $1,174,000 after acquiring an additional 747 shares during the last quarter. Palisade Capital Management LLC NJ increased its position in shares of Johnson & Johnson by 0.3% in the 1st quarter. Palisade Capital Management LLC NJ now owns 93,141 shares of the company’s stock valued at $16,507,000 after buying an additional 250 shares in the last quarter. Lmcg Investments LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at $12,462,000. Tandem Investment Advisors Inc. increased its position in shares of Johnson & Johnson by 4.8% in the 1st quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after buying an additional 15,003 shares in the last quarter. Finally, Argent Advisors Inc. increased its position in shares of Johnson & Johnson by 6.6% in the 1st quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock valued at $3,504,000 after buying an additional 1,218 shares in the last quarter. Institutional investors own 68.78% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. UBS Group reduced their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Morgan Stanley upped their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Citigroup reduced their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. SVB Leerink reduced their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Finally, Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating for the company. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Trading Down 0.9 %

Johnson & Johnson stock opened at $166.13 on Wednesday. The firm has a 50-day moving average of $173.32 and a 200-day moving average of $174.48. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. The company has a market cap of $436.79 billion, a price-to-earnings ratio of 24.18, a P/E/G ratio of 3.22 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. Johnson & Johnson’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.48 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.72%. Johnson & Johnson’s payout ratio is 65.79%.

Insider Activity

In other news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.